The THIO-Libtayo therapy mixture could also be a helpful therapy possibility for sufferers with NSCLC that’s immune to checkpoint inhibitors.
Sufferers with superior non-small cell lung most cancers (NSCLC) that’s immune to checkpoint inhibitors noticed advantages from therapy with THIO (6-thio-2’-deoxyguanosine; 6-thio-dG) together with Libtayo (cemiplimab), researchers have reported.
Findings from the part 2 THIO-101 scientific trial have been introduced through the 2024 Society for Immunotherapy of Most cancers (SITC) Annual Assembly.
On the knowledge cutoff on Sept. 16, 2024, amongst 69 evaluable sufferers who accomplished not less than one post-baseline evaluation, 9 skilled partial responses (PRs) and 7 achieved confirmed PRs by way of a second scan. Nineteen sufferers had survival follow-ups exceeding 12 months; all 9 sufferers within the second line of remedy have been ongoing follow-ups, eight of 10 sufferers within the third line have been ongoing follow-ups and one affected person had acquired 25 cycles of remedy.
Sufferers handled within the third-line setting (20 sufferers) achieved a illness management fee (DCR) of 85%. At a median survival follow-up of 11.5 months, 70% of those sufferers crossed the 5.8-month general survival (OS) threshold and 85% crossed the two.5-month progression-free survival (PFS) threshold.
Glossary
Illness management fee (DCR): sufferers who had an entire response, partial response or secure illness from therapy.
Total survival (OS): the time a affected person lives, no matter illness standing.
Development-free survival (PFS): the time a affected person lives with out their illness spreading or worsening.
Goal response fee (ORR): sufferers whose illness responded partially or fully to therapy.
Elevated aspartate aminotransferase (AST): elevated enzymes that point out liver harm.
Elevated alanine aminotransferase (ALT): elevated enzymes that point out liver harm or illness.
Neutropenia: decreased ranges of neutrophils, a sort of white blood cell.
Moreover, eight sufferers who acquired THIO at a dose of 180 milligrams (mg) plus Libtayo within the third line of remedy skilled an goal response fee (ORR) of 38%. At a median survival follow-up of 11.4 months, the median PFS was 5.5 months, 75% of sufferers crossed the 5.8-month OS threshold and 88% crossed the two.5-month PFS threshold. The 6-month OS fee was 75%.
“This routine demonstrated an ORR of 38% within the chosen 180-mg dose, considerably surpassing the roughly 6% [ORR] seen with customary therapies in a closely pretreated inhabitants,” Dr. Victor Zaporojan, the senior medical director of MAIA Biotechnology, stated through the presentation. “The THIO and [Libtayo] mixture not solely presents a sturdy and efficient therapy for superior NSCLC but in addition [has the] potential to redefine customary care [with] promising response charges and prolonged survival advantages.”
THIO was granted orphan drug designation from the FDA in April 2022 for the therapy of sufferers with hepatocellular carcinoma. In August 2022, the agent additionally acquired orphan drug designation from the FDA in small cell lung most cancers.
READ MORE: THIO-Libtayo Routine Is ‘Encouraging’ for Relapsed NSCLC
THIO-101 was an open-label, multicenter research that enrolled grownup sufferers with superior NSCLC who skilled illness development or relapse following therapy with an immune checkpoint inhibitor within the first or second line of remedy.
By way of security, therapy with THIO plus Libtayo was typically well-tolerated and most negative effects have been grade 1 (delicate) or 2 (reasonable); no dose-limiting toxicities have been reported through the security lead-in. Within the general inhabitants, any-grade treatment-emergent negative effects occurring in not less than two sufferers included elevated aspartate aminotransferase (AST; 26.6%), elevated alanine aminotransferase (ALT; 22.8%), nausea (12.7%) and neutropenia (5.1%).
Grade 3 (extreme) or increased treatment-emergent negative effects included elevated ALT (11.4%), elevated AST (11.4%) and neutropenia (3.8%). Enrollment into the 360-mg group was paused following an occasion of grade 4 (life-threatening) liver operate check elevation.
In November 2023, the 180-mg dose degree of THIO was chosen as one of the best dose. Half B of the research is evaluating THIO at this dose and accomplished enrollment in February 2024.
Reference
“Telomere-targeting agent THIO in sequential mixture with cemiplimab demonstrates long run therapeutic advantages past therapy cessation. A part 2 trial in superior immune checkpoint inhibitor resistant non-small cell lung most cancers sufferers,” by Dr. Tibor Csoszi, et al., introduced at 2024 SITC Annual Assembly.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
